Eddid Financial: PEGBIO CO-B (2565.HK) Launched Its IPO

PEGBIO CO-B (2565.HK), a biotechnology company focused on developing innovative therapies for chronic diseases, launched its IPO today.

PEGBIOCO-B intends to issue 19,283,500 shares, with an offer price HKD 15.6 per share. Each lot will consist of 500 shares, requiring an entry fee of approximately HK$ 7,878.66. The maximum amount raised through this IPO is estimated to be around HK$301 million. The offer period will run from May 19 - 22, and the company is expected to be listed on May 27.

The Company’s Core Product PB-119 is one of the earliest domestically developed long-acting GLP-1 receptor agonists in China, primarily designed for the first-line treatment of type 2 diabetes mellitus (“T2DM”) and obesity. The new drug application for PB-119 in China for T2DM was accepted by the National Medical Products Administration in September 2023, and is expected to receive the approval and commercially launch for the treatment of T2DM in China in 2025.

The company is dedicated to advancing innovative therapies for chronic diseases, and has developed a leading, differentiated and balanced drug portfolio primarily targeting significant medical needs in the chronic and metabolic disease market, including T2DM, obesity and NASH (an advanced form of non-alcoholic fatty liver disease).

Eddid Financial is one of the Joint Lead Managers and Joint Bookrunners for the launch of PEGBIO CO-B’s IPO.

The IPO subscription period kicks off today. Interested investors should stay tuned for updates.

---

Prospectus: https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0519/2025051900013.pdf

Investment involves risks, be cautious of trading.

Information Details

Eddid Financial: PEGBIO CO-B (2565.HK) Launched Its IPO